HALO News and Press, Halozyme Therapeutics Inc. From 06/07/22

Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy PR Newswire SAN DIEGO , June 7, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the commercial laun...

One of the largest tech deals in M&A history was announced last week. Chipmaker Broadcom entered into an agreement to acquire VMware for $69 billion in a cash or stock deal. Broadcom's acquisition of VMware will be reviewed by either the FTC or the DOJ, the Committee on Foreig...

Halozyme Therapeutics announced that they are acquiring Antares Pharma at $5.60 per share in cash, for a total of ~$960M. The deal is expected to close in 1H of 2022. Antares develops products utilizing their drug delivery systems and has multiple royalty streams for their auto-inject...

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...

Halozyme Therapeutics, Inc. (HALO) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mike DiFiore - Eve...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Halozyme Therapeutics press release (NASDAQ:HALO): Q1 Non-GAAP EPS of $0.47 misses by $0.02. Revenue of $117.3M (+31.8% Y/Y) misses by $10.95M. Shares +0.68%. For further details see: Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M

Halozyme Reports First Quarter 2022 Results PR Newswire First Quarter Revenue of $117.3 million , Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalt...

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 o...

Value investing consists of buying unappreciated or ignored stocks at attractive prices. Value investing avoids the current stock market darlings. Lakonishok created a stir in the finance community through his research in behavioral finance. For further details see: Find...